Skip to content

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk, Scott Shannon, Michael P. Bogenschutz, Yevgeniy Gelfand, Casey Paleos, Christopher R. Nicholas, Sylvestre Quevedo, Brooke Balliett, Scott Hamilton, Michael C Mithoefer, Sarah Kleiman, Kelly Parker-Guilbert, Keren Tzarfaty, Charlotte Harrison, Alberdina De Boer, Rick Doblin, Berra Yazar-Klosinski

Nature Medicine November 1, 2024 DOI: 10.1038/s41591-024-03331-w (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized Placebo-controlled Peer reviewed
Topics Psychedelic-assisted therapy MDMA PTSD
Keywords PTSD Treatment Trauma therapy PTSD Relief Trauma recovery Mental health treatment Psychological treatment Psychiatric treatment Symptom reduction Lasting improvements MDMA-Assisted Therapy MDMA Therapy Ecstasy therapy Drug-assisted psychotherapy Therapeutic MDMA Clinical trials Medical research Drug trials Randomized controlled trials Placebo-controlled studies Scientific study Research study Rigorous trial Psychological well-being Psychiatric health Emotional health Mental wellness Mental healthcare Hope
Citations 4

Abstract

In the version of the article initially published, some members of the MAPP2 Study Collaborator Group were listed only in the Supplementary Information. Charlotte Harrison, Berra Yazar-Klosinski, Wael Garas, Darrick May, Cole Marta, Susan Walker, Elizabeth Nielson, Gregory Wells, Randall Brown, Revital Amiaz, Yair Wallach, Ray Worthy, Alia Lilienstein and Amy Emerson have now been added to the main list of collaborators in the HTML and PDF versions of the article.

Citations in the library

Cited by 5

Related reading

Explore topics

Psychedelic-assisted therapy MDMA PTSD

By condition and practice

MDMA and psychedelic-assisted therapy MDMA for PTSD